Akari Therapeutics, Plc (AKTX)

NASDAQ: AKTX · IEX Real-Time Price · USD

1.166

-0.004 (-0.32%)

At close: Apr 19, 2024, 4:00 PM

1.110

-0.056 (-4.82%)

After-hours: Apr 19, 2024, 4:00 PM EDT

Akari Therapeutics, Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2010
Selling, General & Admin	11.36	13.53	8.08	9.16	8.22	11.69	11.8	9.94	5.5	0.3	Upgrade
Research & Development	5.45	9.56	9.13	8.82	8.74	11.8	23.29	17.31	5.8	1.62	Upgrade
Other Operating Expenses	0	0	0	0	0	-2.7	2.7	0	19.28	0	Upgrade
Operating Expenses	16.81	23.09	17.21	17.98	16.96	20.79	37.78	27.25	30.58	1.92	Upgrade
Operating Income	-16.81	-23.09	-17.21	-17.98	-16.96	-20.79	-37.78	-27.25	-30.58	-1.92	Upgrade
Interest Expense / Income	0	0	0	0	0	0	0	0	26.03	0.01	Upgrade
Other Expense / Income	-6.8	-5.34	0.21	-0.9	-0.12	-0.29	-2.38	-9.11	-11.29	0.02	Upgrade
Pretax Income	-10.01	-17.75	-17.42	-17.08	-16.85	-20.5	-35.4	-18.14	-45.32	-1.95	Upgrade
Net Income	-10.01	-17.75	-17.42	-17.08	-16.85	-20.5	-35.4	-18.14	-45.32	-1.95	Upgrade
Shares Outstanding (Basic)	9,789	6,243	4,292	3,159	1,831	1,540	1,247	1,178	852	86	Upgrade
Shares Outstanding (Diluted)	9,789	6,243	4,292	3,159	1,831	1,540	1,247	1,178	852	86	Upgrade
Shares Change	56.79%	45.46%	35.87%	72.53%	18.87%	23.49%	5.91%	38.21%	896.41%	305.77%	Upgrade
EPS (Basic)	-	-	-	-20.00	-20.00	-20.00	-60.00	-40.00	-100.00	-40.00	Upgrade
EPS (Diluted)	-	-	-	-20.00	-20.00	-20.00	-60.00	-40.00	-100.00	-40.00	Upgrade
Free Cash Flow	-16.43	-21.5	-18.85	-16.95	-12.92	-22.77	-31.64	-24.68	-4.98	-1.48	Upgrade
Free Cash Flow Per Share	-3.36	-6.89	-8.78	-10.73	-14.11	-29.57	-50.73	-41.91	-11.68	-34.54	Upgrade
EBITDA	-10	-17.74	-17.42	-17.07	-16.83	-20.46	-35.36	-18.1	-19.28	-1.94	Upgrade
Depreciation & Amortization	0	0	0	0.01	0.02	0.04	0.04	0.04	0.01	0	Upgrade
EBIT	-10.01	-17.75	-17.42	-17.08	-16.85	-20.5	-35.4	-18.14	-19.29	-1.94	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).